Expert Opinion on Investigational Drugs, Volume 33, Issue 3 (2024)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Investigational Drugs, Volume 33, Issue 3 (2024)

See all volumes and issues
Volume 33, 2024 Vol 32, 2023 Vol 31, 2022 Vol 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994
Download citations Download PDFs Download issue

Special Report

Report
KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem
Carlo María Cicala, Iván Olivares-Rivas, Jon Ander Aguirre-Carrillo & César Serrano
Pages: 159-170
Published online: 14 Feb 2024
AbstractforKIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem | Full Text | References | PDF (1.4 MB) | EPUB
  • 165 Views
  • 0 CrossRef citations
  • 0Altmetric
Report
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions
Rafael Rosell, Carlos Pedraz-Valdunciel, Anisha Jain, Chandan Shivamallu & Andrés Aguilar
Pages: 171-182
Published online: 23 Feb 2024
AbstractforDeterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions | Full Text | References | PDF (5.7 MB) | EPUB
  • 117 Views
  • 0 CrossRef citations
  • 0Altmetric

Perspective

Comment
GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates
Deanne H Hryciw, Rhiannon K Patten, Raymond J Rodgers, Joseph Proietto, Dana S Hutchinson & Andrew J McAinch
Pages: 183-190
Published online: 23 Feb 2024
AbstractforGPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates | Full Text | References | PDF (279.9 KB) | EPUB
  • 117 Views
  • 0 CrossRef citations
  • 0Altmetric

Review

Review Article
Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies
Henriette Farkas & Zsuzsanna Balla
Pages: 191-200
Published online: 26 Feb 2024
AbstractforKallikrein inhibitors for angioedema: the progress of preclinical and early phase studies | Full Text | References | PDF (829.7 KB) | EPUB
  • 126 Views
  • 0 CrossRef citations
  • 0Altmetric
Review Article
Duchenne muscular dystrophy: promising early-stage clinical trials to watch
Annie Tang & Toshifumi Yokota
Pages: 201-217
Published online: 06 Feb 2024
AbstractforDuchenne muscular dystrophy: promising early-stage clinical trials to watch | Full Text | References | PDF (3.1 MB) | EPUB
  • 451 Views
  • 0 CrossRef citations
  • 0Altmetric
Review Article
Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs
Shilan Mozaffari, Shekoufeh Nikfar & Mohammad Abdollahi
Pages: 219-228
Published online: 23 Feb 2024
AbstractforDrugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs | Full Text | References | PDF (313.5 KB) | EPUB
  • 142 Views
  • 0 CrossRef citations
  • 0Altmetric
Review Article
Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials
Dominik Kiem, Matthias Ocker, Richard Greil, Daniel Neureiter & Thomas Melchardt
Pages: 229-242
Published online: 23 Feb 2024
AbstractforEnhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials | Full Text | References | PDF (1.6 MB) | EPUB
  • 139 Views
  • 0 CrossRef citations
  • 0Altmetric
Review Article
Investigational pharmacological agents for the treatment of ARDS
Katyayini Aribindi, Michelle Lim, Satyan Lakshminrusimha & Timothy Albertson
Pages: 243-277
Published online: 27 Feb 2024
AbstractforInvestigational pharmacological agents for the treatment of ARDS | Full Text | References | PDF (3.9 MB) | EPUB
  • 219 Views
  • 0 CrossRef citations
  • 0Altmetric
Review Article
A modest proposal: targeting αv integrin-mediated activation of latent TGFbeta as a novel therapeutic approach to treat scleroderma fibrosis
Andrew Leask, Asmaa Fadl & Angha Naik
Pages: 279-285
Published online: 26 Feb 2024
AbstractforA modest proposal: targeting αv integrin-mediated activation of latent TGFbeta as a novel therapeutic approach to treat scleroderma fibrosis | Full Text | References | PDF (1.3 MB) | EPUB
  • 126 Views
  • 0 CrossRef citations
  • 0Altmetric

Explore articles

Explore the most recently published articles

Investigational drugs for the treatment of acromegaly: new agents to transform therapy
Rosa Pirchio et al.
Review Article | Published online: 30 Apr 2024
Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects
Cheng Sun et al.
Article | Published online: 30 Apr 2024
Frontotemporal dementia: from genetics to therapeutic approaches
Francesca R. Buccellato et al.
Review Article | Published online: 30 Apr 2024
Open Access
Drugs in preclinical and early clinical development for the treatment of chagas disease: the current status
Fernanda Karoline Vieira da Silva Torchelsen et al.
Review Article | Published online: 30 Apr 2024
View all latest articles